Beta Bionics (NASDAQ:BBNX) Coverage Initiated at Wolfe Research

Investment analysts at Wolfe Research began coverage on shares of Beta Bionics (NASDAQ:BBNX - Get Free Report) in a research report issued to clients and investors on Friday, Marketbeat reports. The brokerage set an "outperform" rating and a $20.00 price target on the stock. Wolfe Research's target price would suggest a potential upside of 16.28% from the stock's previous close.

BBNX has been the topic of a number of other reports. Stifel Nicolaus initiated coverage on shares of Beta Bionics in a research report on Monday, February 24th. They issued a "buy" rating and a $25.00 price target on the stock. Robert W. Baird started coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They issued a "neutral" rating and a $20.00 target price for the company. Baird R W upgraded shares of Beta Bionics to a "hold" rating in a report on Thursday, February 20th. Piper Sandler initiated coverage on shares of Beta Bionics in a report on Monday, February 24th. They issued an "overweight" rating and a $26.00 price target for the company. Finally, Bank of America initiated coverage on shares of Beta Bionics in a report on Monday, February 24th. They set a "buy" rating for the company. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Beta Bionics presently has a consensus rating of "Moderate Buy" and an average target price of $23.13.

Beta Bionics Stock Performance

Shares of NASDAQ:BBNX traded up $1.84 on Friday, hitting $17.20. 1,228,265 shares of the company were exchanged, compared to its average volume of 485,303. The firm's 50 day moving average price is $12.38. Beta Bionics has a one year low of $8.89 and a one year high of $24.50.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

Institutional Trading of Beta Bionics

A number of large investors have recently added to or reduced their stakes in BBNX. Strs Ohio acquired a new stake in shares of Beta Bionics during the 1st quarter worth about $29,000. Corebridge Financial Inc. bought a new position in Beta Bionics in the 1st quarter valued at about $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Beta Bionics in the 1st quarter valued at about $95,000. MetLife Investment Management LLC bought a new stake in shares of Beta Bionics during the 1st quarter valued at approximately $102,000. Finally, Deutsche Bank AG bought a new stake in shares of Beta Bionics during the 1st quarter valued at approximately $148,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.